Open AccessP506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA
Author(s) -
Bazinet A.,
Kadia T.,
Short N.,
Borthakur G.,
Wang S.,
Loghavi S.,
Jorgensen J.,
Patel K.,
DiNardo C.,
Daver N.,
Alvarado Y.,
Haddad F.,
Pierce S.,
Andreeff M.,
Jabbour E.,
Konopleva M.,
Kantarjian H.,
Ravandi F.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844912.65235.a5
Subject(s) - medicine , cytarabine , oncology , minimal residual disease , proportional hazards model , venetoclax , anthracycline , fludarabine , myeloid leukemia , leukemia , chronic lymphocytic leukemia , chemotherapy , cancer , breast cancer , cyclophosphamide